GeekWire23d
Seattle genomics startup Variant Bio signs deal with Novo Nordisk worth up to $50M
A rooftop deck at Variant Bio’s Seattle offices have a view of the city’s landmark Space Needle. (Cory Parris Photo) Variant Bio today announced a partnership with Novo Nordisk for disease ...
The New York Times24d
Drug Company to Share Revenues With Indigenous People Who Donated Their Genes
On Tuesday, his company, Variant Bio, based in Seattle, announced a $50 million collaboration with the drugmaker Novo Nordisk to develop drugs for metabolic disorders, including diabetes and ...
Bloomberg on MSN9d
Alzheimer’s drugs eyed as next big obesity-like opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Novo Nordisk Shares Still Have a Long Road Back from 40% Slump
Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
Hosted on MSN23d
Seattle genomics startup Variant Bio signs deal with Novo Nordisk worth up to $50M
Variant Bio today announced a partnership with Novo Nordisk for disease research and development that could total $50 million for the biotech startup. The Seattle company is working with ...